Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Advanced Biomed Inc. ( (ADVB) ).
Advanced Biomed Inc. announced that on December 23, 2025, it entered into and closed an agreement to sell 100% of the shares of its Hong Kong subsidiary, Advanced Biomed (HK) Limited, including all associated intellectual property such as that of Shanghai Sglcell Biotech Co., Ltd., to an unrelated buyer, Wei Ha Hui, for US$23,000, following unanimous approval by the company’s board. In a December 30, 2025 press release, CEO Dr. Yi Lu said the divestiture responds to evolving clinical trial and data regulations in China and forms part of a strategic realignment that will centralize all clinical trials in the company’s Taiwan subsidiary, signaling a shift in operational focus that could streamline product development and commercialization while reducing the firm’s exposure to regulatory complexity in mainland China and Hong Kong.
More about Advanced Biomed Inc.
Advanced Biomed Inc., a Nevada-based biotechnology company listed on Nasdaq, specializes in innovative biomedical technologies for cancer detection and precision medicine. Operating primarily through its Taiwan subsidiary, the company has developed a proprietary microfluidic platform that integrates semiconductor and biotechnology to enable advanced circulating tumor cell detection, enrichment and analysis, with a portfolio of devices and biochips aimed at cancer screening, diagnosis, treatment selection and prognosis assessment, and regulatory clearances underway in Taiwan alongside plans for global expansion.
Average Trading Volume: 1,322,657
Technical Sentiment Signal: Strong Sell
Current Market Cap: $7.22M
For detailed information about ADVB stock, go to TipRanks’ Stock Analysis page.